1-4 of 4
Peter Forsyth, MD
Close
Sort by
Journal Articles

The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Sepideh Mokhtari, MD, Justin M Asquith, MD, Christina A Bachmeier, PharmD, Michael D. Jain, MD PhD, Peter Forsyth, MD, Frederick L. Locke, MD, Youngchul Kim, PhD, Aleksandr Lazaryan, MD PhD MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 5627.
https://doi.org/10.1182/blood-2019-122343
Published: 2019
Journal Articles

What Is The Optimal Dose Of Methotrexate In Primary Central Nervous System Lymphoma Treatment Regimens?

Samir Dalia, MD, Samantha L Price, PharmD, Peter Forsyth, MD, Celeste M. Bello, MD, Bijal D. Shah, MD, Lubomir Sokol, MD, Ph.D, Eduardo M. Sotomayor, MD, Michael V. Jaglal, MD
Journal: Blood
Blood (2013) 122 (21): 3040.
https://doi.org/10.1182/blood.V122.21.3040.3040
Published: 2013
Journal Articles

Treatment with Intermediate Subviral Particles Overcomes Resistance to Reovirus Induced Oncolysis in Mantle Cell Lymphoma Cell Lines.

Gwyn Bebb, BMBCh, PhD, Huong Muzik, BSc, Tom Alain, BSc, Karen Dong, BSc, Chandini Thirukkamaran, PhD, Peter Forsyth, MD, PhD, Don Morris, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 2417.
https://doi.org/10.1182/blood.V106.11.2417.2417
Published: 2005
Journal Articles

High Dose Thiotepa, Busulfan, Cyclophosphamide (TBC) and Autologous Hematopoietic Stem Cell Transplantation (ASCT) without Whole Brain Radiotherapy (WBRT) for Primary Central Nervous System Lymphoma (PCNSL).

Douglas A. Stewart, MD, FRCPC, Peter Forsyth, MD, Ahsan Chaudhry, MD, Oluyemi Jeje, MD, Donald Morris, MD, FRCPC, Lynn Savoie, MD, FRCPC, Chris Brown, MD, FRCPC, James R. Russell, MB, FRCPC
Journal: Blood
Blood (2004) 104 (11): 911.
https://doi.org/10.1182/blood.V104.11.911.911
Published: 2004